Fig. 4From: Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancerProgression-free survival (PFS) according to treatment with gemcitabine and oxaliplatin (GEMOX) or GEMOX with erlotinib (GEMOXT) (a) and early tumor shrinkage (ETS) 6 weeks after treatment (b) in patients with wild-type KRAS tumorsBack to article page